Pt 1: Congenital Heart Disease: Why Current Treatments Aren’t Enough

Baby in hospital bed with mother

The Problem We Can't Change

Congenital heart disease (CHD) is the most common birth defect, affecting approximately 1 in every 100 babies born. Yet despite decades of medical progress, it remains one of the greatest unmet challenges in medicine.

CHD isn’t a single disease. It’s a collection of structural abnormalities that develop before birth, affecting the heart’s chambers, valves, or major blood vessels. These defects can limit blood flow, reduce heart function, and require lifelong medical care.

For many children, surgery begins within the first days or months of life. These procedures can improve circulation and help patients survive, but they do not repair the underlying structural problem.

That distinction is important.

Modern medicine has transformed care for diseases like cancer and diabetes through targeted medications. But congenital heart disease is different. There is no medication capable of rebuilding a malformed heart. Today’s therapies largely focus on managing symptoms, supporting circulation, and extending quality of life.

Fortunately, advances in pediatric cardiac care mean many children born with CHD are now living well into adulthood. Today, adults with congenital heart disease outnumber children with the condition. While this is a remarkable achievement, it also means millions of people continue to live with repaired—but not cured—hearts.

At HeartWorks, we believe patients deserve more than lifelong management. They deserve therapies designed to restore heart function and create new possibilities for the future.

Understanding the problem is the first step toward solving it.

This article is Part 1 of our HeartWorks 101 educational series. Continue the journey by learning why HeartWorks was created and why congenital heart disease required an entirely new model for innovation.

Share the Post:

Related Posts

HeartWorks lab team member reviewing electronic manufacturing documentation for congenital heart disease cell therapy production

Innovation Behind the Scenes: Our Manufacturing Lab Goes Digital

Behind every personalized CHD therapy at HeartWorks is a nine-month manufacturing process that generates more than 500 pages of documentation. A new electronic system built specifically for HeartWorks’ production workflow is changing how that information is captured, tracked, and used – making the path from a patient’s skin biopsy to their cardiac cells more precise, consistent, and data-driven than ever

Read More
Dr. Tim Nelson, HeartWorks CEO, featured on the Before the Cure podcast episode cover art

HeartWorks Featured on Before the Cure

Did you know your medical records could help shape the future of CHD treatment? The Co-op at HeartWorks is a free, secure database where CHD patients can upload their records — putting their data directly in the hands of researchers working to develop better therapies. Co-op members are notified when they qualify for new clinical trials, and their data helps identify where gaps in care exist. If you’re living with CHD, joining the Co-op is one of the most powerful things you can do

Read More

The Co-op at HeartWorks: How CHD Patient Data Is Changing Heart Research

Did you know your medical records could help shape the future of CHD treatment? The Co-op at HeartWorks is a free, secure database where CHD patients can upload their records — putting their data directly in the hands of researchers working to develop better therapies. Co-op members are notified when they qualify for new clinical trials, and their data helps identify where gaps in care exist. If you’re living with CHD, joining the Co-op is one of the most powerful things you can do

Read More

Send A Message

This field is for validation purposes and should be left unchanged.
Name(Required)
Please let us know what's on your mind. Have a question for us? Ask away.